Enobia Announces Completion Of Enrollment In Third Phase II Hypophosphatasia Study Of ENB-0040, A Bone Targeted Enzyme Replacement Therapy
Links shared publicly online about this topic.
- 480total visits
Enobia Announces Completion Of Enrollment In Third Phase II Hypophosphatasia Study Of ENB-0040, A Bone Targeted Enzyme Replacement Therapy
Enobia Pharma Inc., announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adul
View full resource at medicalnewstoday.com
Most Recently Shared on February 25, 2011 at 8:05 pm By:
Enobia Announces Completion Of Enrollment In Third Phase II Hypophosphatasia Study Of ENB-0040, A Bone Targeted Enzyme... http://mnt.to/3RBV
Also Shared By:
Enobia completes patient enrollment in ENB-0040 Phase II study for HPP
news-medical.net — “Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.” View full resource at news-medical.net
Most Recently Shared on February 25, 2011 at 11:22 am By:
Genetics News: Enobia completes patient enrollment in ENB-0040 Phase II study for HPP: Enobia Pharma Inc., today... http://bit.ly/gqmKFN
Advertisement
MNT Bones/Orthopedic
@mnt_bones
Enobia Announces Completion Of Enrollment In Third Phase II Hypophosphatasia Study Of ENB-0040, A Bone Targeted Enzyme... http://mnt.to/3RBV
1 year ago...